Institutional members access full text with Ovid®

Share this article on:

Fibrate treatment for primary biliary cirrhosis

Cuperus, Frans J.C.; Halilbasic, Emina; Trauner, Michael

Current Opinion in Gastroenterology: May 2014 - Volume 30 - Issue 3 - p 279–286
doi: 10.1097/MOG.0000000000000056
BILIARY TRACT: Edited by Gregory J. Gores

Purpose of review Primary biliary cirrhosis (PBC) can lead to end-stage liver disease and death. Ursodeoxycholic acid (UDCA) treatment can normalize serum liver enzymes in PBC, and such UDCA-responsive patients have a similar life expectancy as age and sex-matched controls. Nearly up to 50% of the patients with PBC, depending on sex and age at diagnosis, show an incomplete biochemical response to UDCA and require additional/alternative treatment. The purpose of this review is to critically evaluate the molecular mechanisms and clinical benefit of fibrate treatment in these patients.

Recent findings Fibrates have anticholestatic, anti-inflammatory, and antifibrotic effects in animal and in-vitro studies. The mechanisms that underlie these effects are complementary, and largely mediated through activation of peroxisome proliferator activated receptors. Fibrate treatment ameliorated liver biochemical tests in UDCA unresponsive patients, either as mono-therapy or in combination with UDCA. These results, however, were obtained in case series and small pilot studies. The results of phase III studies, such as the Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (BEZURSO) trial, are currently awaited.

Summary A considerable body of observational evidence supports the safety and efficacy of fibrate treatment in PBC patients with an incomplete response to UDCA. These results encourage the evaluation of its effects on liver-related morbidity and mortality in larger clinical trials.

Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria

Correspondence to Michael Trauner, MD, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Währingergürtel 18-20, 1090 Wien, Austria. Tel: +43 0 1 40400 4741; fax: +43 0 1 40400 4735; e-mail:

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins